Founded in 2017, Hims & Hers Health (HIMS -0.37%) is a telemedicine company that sells prescription and over-the-counter drugs online directly to consumers.
Today, Hims & Hers Health provides customers in all 50 states and Washington D.C. access to consultations, primary care services, and other virtual care services from licensed healthcare professionals 100% online.
In addition to an extensive provider network, users can pay to have both prescription and nonprescription products on the platform delivered to their home for free. Many of its nonprescription products are also available for sale at retail locations across the country.
Read on to learn more about this company and how to invest in the stock.
How to buy Hims & Hers Health stock
Because Hims & Hers Health stock is publicly traded, you can easily buy whole or fractional shares through your brokerage account. Here's a step-by-step look at how that would work.
- Open your brokerage account: Log in to your brokerage account where you handle your investments. If you don't have one yet, take a look at our favorite brokers and trading platforms to find the right one for you.
- Fund your account: Transfer money so you’re ready to invest.
- Search for Hims & Hers: Enter the ticker "HIMS" into the search bar to bring up the stock's trading page.
- Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
- Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
- Submit your order: Confirm the details and submit your buy order.
- Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.
Should you invest in Hims & Hers Health?
Hims & Hers Health is appealing to investors looking for growth in virtual healthcare. The company has expanded into high-demand areas like GLP-1 weight loss drugs, a market analysts expect to exceed $100 billion by the end of the decade. It also operates across large, underserved categories such as sexual health and mental health, giving it a broad total addressable market.
Growth has been strong. Subscribers increased 31% year over year in Q2 2025, and management expects $2.3 to $2.4 billion in revenue and up to $335 million in EBITDA for 2025. Its mix of subscription-based care and personalized treatments helps keep customers engaged.
That said, competition in telehealth is intense, and the stock is best suited for investors comfortable with growth-focused businesses rather than those seeking dividends or deep value.
NYSE: HIMS
Key Data Points
Is Hims & Hers Health profitable?
Yes, Hims & Hers Health stock is profitable. The company reported its first profitable quarter at the end of 2023, bringing in $1.2 million in net income. In the second quarter of 2025, it delivered a net income of $42.5 million.
Does Hims & Hers Health pay a dividend?
Hims & Hers Health stock does not pay a dividend and has not announced its intention to start one in the future. Given that the company is investing heavily in its growth at this point in time and is a relatively new business, a dividend seems unlikely anytime soon.
Will Hims & Hers Health stock split?
Hims & Hers Health stock went public in January 2021 via a $1.6 billion special purpose acquisition company (SPAC). The company has not split its stock.
Usually, a company will split its stock when shares become too high or too low, or outpace those of similar companies in the industry, making an investment less accessible to wide groups of investors. Shares of Hims & Hers Health trade around $53 at the time of this article, so a stock split seems highly unlikely at any point in the near future.
The bottom line
Hims & Hers is growing steadily. Revenue and subscribers are consistently on the upswing. Profitability is improving. Its diverse potential audience could prime the company to snag shares in multiple lucrative segments of the telemedicine market.
The telehealth market is a competitive space, but consumers tend to spend on healthcare in a wide range of economic cycles, just as they do consumer staples. That lends a certain level of resilience to companies operating in this space.
Hims & Hers Health is a growth-oriented stock, so it might not be an ideal choice for value-oriented or dividend-seeking investors. However, for investors with an ample buy-and-hold horizon who want a stake in a profitable telehealth business with a steady growth runway ahead, Hims & Hers Health stock may be a solid addition to a long-term investment portfolio.
Related investing topics
FAQ
About the Author
